TABLE 1.
Basic characteristics of the study subjects and the expression levels of the selected mRNA and lncRNA in PBMCs in the validation sample
| (A) Basic characteristics of the study subjects | ||||
|---|---|---|---|---|
| Discovery group | Validation group | |||
| Variable | RA patient (n = 25) | Healthy control (n = 18) | RA patient (n = 35) | Healthy control (n = 35) |
| Gender | Female | Female | Female | Female |
| Age (year) | 45.6 ± 9.84 | 47.11 ± 14.09 | 46.44 ± 10.99 | 47.57 ± 13.99 |
| BMI (kg/m2) | 22.07 ± 3.31 | 22.32 ± 2.79 | 22.24 ± 3.67 | 22.32 ± 2.79 |
| DAS28 | 4.46 ± 0.99 | n.d. | 5.08 ± 1.32 | n.d. |
| CRP (mg/L) | 13.51 + 16.74 | n.d. | 18.37 ± 31.17 | n.d. |
| ESR (mm/h) | 42.61 ± 27.5 | n.d. | 48.29 ± 29.46 | n.d. |
| TJC | 8.64 ± 6.49 | n.d. | 10 ± 7.7 | n.d. |
| SJC | 5.48 ± 3.83 | n.d. | 6.79 ± 5.43 | n.d. |
| (B) The expression levels of the selected mRNA and lncRNA in PBMCs in the validation sample | ||||
|---|---|---|---|---|
| lncRNA | Chromosome | Fold change | p‐Value | Class |
| CYTOR | 17q11.2 | 1.08 | 0.67 | Intergenic |
| DQ593252 | 11q12.3 | 1.21 | 0.05 | Intergenic |
| E2F3‐IT1 | 6p22.3 | 1.73 | 0.03 | Intronic |
| uc.265 | 9q31.1 | 1.35 | 0.02 | Antisense |
| INE2 | Xp22.2 | 1.43 | 0.049 | Antisense |
| mRNA | ||||
| DDX58 | 9p21.1 | 1.06 | 0.67 | DExD/H‐box helicase 58 |
| IFI16 | 1q23.1 | 1.09 | 0.35 | Interferon gamma inducible protein 16 |
| LDLR | 19p13.2 | 2.13 | <0.001 | Low‐density lipoprotein receptor |
| PLSCR1 | 3q24 | ‐1.67 | <0.001 | Phospholipid scramblase 1 |
| PARP9 | 3q21.1 | 1.39 | 0.015 | Poly(ADP‐ribose) polymerase family member 9 |
Abbreviations: BMI, body mass index; DAS28,28 joint Disease Activity Score; CRP, C reactive protein; ESR, equivalent series resistance; TJC, tender joint count; SJC, swollen joint count; n.d., not determined.
Notes: Variables were expressed as the mean ± SD. p‐Value represents the significance for the difference between RA patients(n = 35) and healthy controls(n = 35).